Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Advanced Solid Tumors 3Vulvar Neoplasms 2Vaginal Neoplasms 2Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor 1Solid Malignancies 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 10Docetaxel 8senaparib 7Injections 7Capecitabine 7Paclitaxel 6Cisplatin 6Irinotecan 5Fluorouracil 5Leucovorin 4Cyclophosphamide 4Bevacizumab 4tislelizumab 3pertuzumab 3fludarabine 3atezolizumab 3Rifampin 3Oxaliplatin 3Itraconazole 3Gemcitabine 3ontuxizumab 2navoximod 2fluzoparib 2durvalumab 2Trastuzumab 2Nivolumab 2Midazolam 2Hydroxychloroquine 2Carboplatin 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumor × tremelimumab × Clear all
NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
72 enrolled 23 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡